| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| 21.08.2026 | Gregorio Marañón Hospital Implants World’s First Personalized Metamaterial Bone Prosthesis | The Advanced Planning and 3D Manufacturing Unit (UPAM3D) at Gregorio Marañón University General Hospital, part of the Community of Madrid, has reportedly designed, manufactured and implanted the world’s first personalized metamaterial bone ... |
| 31.07.2026 | Datroway approved in EU for TNBC | Datroway approved in EU for TNBC
Fri, Jul 31, 2026 08:48 CET Report this content
31 July 2026
Datroway approved in the EU as only TROP2-directed medicine with overall survival benefit for the 1st-line treatment of patients with metastatic T... |
| 21.07.2026 | ESMO 2026 | Mabwell to Present Latest Clinical Data on Nectin-4-targeting ADC 9MW2821 for Triple Negative Breast Cancer in Oral Presentation | SHANGHAI, July 21, 2026 /PRNewswire/ -- Mabwell (688062.SH, 02493.HK), an innovation-driven biopharmaceutical company with a fully integrated industry chain, will present the latest clinical study results of its novel Nectin‑4‑targeting ADC... |
| 29.06.2026 | Datroway recommended for approval in EU for TNBC | Datroway recommended for approval in EU for TNBC
Mon, Jun 29, 2026 08:00 CET Report this content
29 June 2026
Datroway recommended for approval in the EU by CHMP as 1st-line treatment for patients with metastatic triple-negative breast canc... |
| 18.06.2026 | Mabwell Presents Clinical Results of Nectin-4-Targeting ADC 9MW2821 at 2026 ESMO Gynaecological Cancers Congress | SHANGHAI, June 18, 2026 /PRNewswire/ -- Mabwell (688062.SH, 02493.HK), an innovation-driven biopharmaceutical company with a fully integrated industry chain, presented two latest clinical study results of its independently developed Nectin-... |
| 01.06.2026 | ASCO 2026 | CStone Presents Updated Clinical Data for CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody), Reinforcing Triple-Target Synergy and Delivering Strong Proof-of-Concept | First-line NSCLC – Compelling Activity Across All PD-L1 Subgroups
In first-line non-small cell lung cancer (NSCLC) patients with high PD-L1 expression (TPS ≥50%), CS2009 monotherapy achieved an objective response rate (ORR) of 81.3% and a d... |
| 29.05.2026 | Imfinzi approved in US for early bladder cancer | Imfinzi approved in US for early bladder cancer
Fri, May 29, 2026 08:00 CET Report this content
29 May 2026
Imfinzi approved in the US in first and only immunotherapy combination for patients with BCG-naïve, high-risk non-muscle-invasive bl... |
| 26.05.2026 | Datroway approved in US for 1L triple-negative BC | Datroway approved in US for 1L triple-negative BC
Tue, May 26, 2026 08:00 CET Report this content
26 May 2026
Datroway approved in the US as first TROP2-directed antibody drug conjugate for 1st-line treatment of patients with metastatic tri... |
| 18.05.2026 | Enhertu approved in two HER2+ early BC settings | Enhertu approved in two HER2+ early BC settings
Mon, May 18, 2026 08:05 CET Report this content
18 May 2026
Enhertu approved in the US for two new indications for patients with HER2-positive early breast cancer
Approved for use before surge... |
| 26.03.2026 | CStone Updated Clinical Progress and Key Phase I/II Data for CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody) | Key Highlights:
Excellent Safety Profile: As of mid-March 2026, 113 heavily pretreated patients with solid tumors have been enrolled in the Phase I trial of CS2009, with a median follow-up of approximately 6 months. The more mature data con... |
| 24.03.2026 | DualityBio (9606.HK) Announces 2025 Annual Results | HONG KONG, March 24, 2026 /PRNewswire/ -- Duality Biotherapeutics, Inc. (Hong Kong Stock Exchange Code: 09606.HK, hereinafter referred to as "DualityBio" or the "Company"), a leading global clinical-stage innovative biop... |
| 18.03.2026 | Kelun-Biotech to Present the Final OS Analysis of Sacituzumab Tirumotecan (Sac-TMT) from the OptiTROP-Lung03 Study | CHENGDU, China, March 18, 2026 /PRNewswire/ -- The 2026 European Lung Cancer Congress (ELCC) will be held in Copenhagen, Denmark, from March 25 to 28, 2026 (local time). At this congress, the final OS analysis from the pivotal study (OptiTR... |
| 06.03.2026 | CARsgen Therapeutics Announces 2025 Annual Results | SHANGHAI, March 6, 2026 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, has announced its 2025 Annual Results.
Business Highlights
Cash and cash e... |
| 04.03.2026 | Gene Solutions Announces Strategic Entry into Türkiye with Robust Real-World Evidence at the 2nd International Hereditary Cancers Congress 2026 | In Partnership with ATC Genomics, the Company Presented One of Asia's Largest Real-World Datasets (n=12,281) for AI-Powered Multi-Cancer Early Detection (MCED) and Showcased its Clinically Validated ctDNA-Powered Oncology Portfolio Across t... |
| 23.02.2026 | CStone Announces MHRA Approval in UK for Sugemalimab in Stage III NSCLC | Following approval by the European Commission (EC), sugemalimab has received a new indication approval from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for stage III non-small cell lung cancer (NSCLC). This marks the s... |
| 19.02.2026 | Elsevier ClinicalKey AI Adds NEJM, The Lancet, and HIPAA Compliance | What You Should Know
The Upgrade: Elsevier has significantly expanded its ClinicalKey AI platform, adding full-text access to over 130 premium medical journals (including NEJM and The Lancet) and clinical guidelines from top medical societi... |
| 14.02.2026 | Alphamab Oncology Announces the First Patient Dosed in a Phase III Clinical Study for Colorectal Cancer of Biparatopic HER2-targeting ADC JSKN003 | SUZHOU, China, Feb. 14, 2026 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that the first patient has been successfully dosed in the Phase III clinical study (Study ID: JSKN003-005) of the biparatopic HER2-targeting anti... |
| 27.01.2026 | Alphamab Oncology Announces the Results of a Phase III Clinical Study of Anbenitamab (KN026) were Published in Annals of Oncology | SUZHOU, China, Jan. 27, 2026 /PRNewswire/ -- Alphamab Oncology (Stock Code: 9966.HK) announced that the results from a phase III clinical study for the treatment of HER2-positive gastric or gastroesophageal junction cancer (GC/GEJ) of anben... |
| 20.01.2026 | Chinese NMPA Accepts New Drug Application for Illuccix for Prostate Cancer Imaging | MELBOURNE, Australia and INDIANAPOLIS, Jan. 20, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces that the Chinese National Medical Products Administration (NMPA) Center for Drug E... |
| 16.01.2026 | Kelun-Biotech Showcases Innovative Achievements and Future Development Strategy at the 44th Annual JPM Healthcare Conference | CHENGDU, China, Jan. 16, 2026 /PRNewswire/ -- From January 12 to 15, 2026, the 44th J.P. Morgan Healthcare Conference (JPMHC) was held in San Francisco, California, USA. Dr. Ge Michael, President and CEO of Sichuan Kelun-Biotech Biopharmace... |
| 14.01.2026 | Head-to-Head Real-World Data: Cadonilimab Outperforms PD-1 Inhibitors in First-Line PD-L1-Low Gastric Cancer | HONG KONG, Jan. 14, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) announced the presentation of a real-world study at the 2026 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI), comparing cadonilimab plus chemo... |
| 20.12.2025 | Gene Solutions Concludes Successful ESMO Asia Congress 2025 with AI-Powered Multi-Omics Liquid Biopsy Symposium and Two Best Poster Awards | SINGAPORE, Dec. 20, 2025 /PRNewswire/ -- Gene Solutions, a pioneering genetic testing company, announced key achievements at the European Society for Medical Oncology (ESMO) Asia Congress 2025—held in Singapore on December 5–7. Highlights i... |
| 12.12.2025 | Cadonilimab (PD-1/CTLA-4) Receives FDA Clearance for Global Phase III First-Line Gastric Cancer Trial Versus Nivolumab | HONG KONG, Dec. 12, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced FDA approval to initiate COMPASSION-37/AK104-311 trial, a global multicenter Phase III trial in gastric cancer evaluatin... |
| 11.12.2025 | HanchorBio Announces Oral Presentation of HCB101 at the ESMO Immuno-Oncology Congress 2025 | International debut underscores emerging role for macrophage checkpoint therapy in gastric cancer, triple-negative breast cancer, and other hard-to-treat solid tumors
TAIPEI, SHANGHAI, AND SAN FRANCISCO, Dec. 11, 2025 /PRNewswire/ -- Hancho... |
| 11.12.2025 | Updated Efficacy Data of Ivonescimab Combined with Chemotherapy as First-Line Treatment for TNBC Presented at ESMO IO 2025 | HONG KONG, Dec. 11, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced the presentation of a Phase II clinical study that included a longer-term efficacy data evaluating ivonescimab (a PD-1/V... |
| 12.11.2025 | - | CAMBRIDGE, Mass., Nov. 12, 2025 /PRNewswire/ -- Cypherpunk Technologies Inc., previously known as Leap Therapeutics, Inc. (Nasdaq:LPTX), a company developing novel therapies for patients with cancer and implementing a digital asset treasury... |
| 03.11.2025 | Tubulis: Second Tranche Of €344 Million Series C Closed To Advance ADC Pipeline | Tubulis announced the second and final closing of its Series C financing round, bringing the total raised to €344 million ($401 million). The round included new investors Fidelity Management & Research Company, Janus Henderson Investors... |
| 24.10.2025 | Global Launch Event for iza-bren Phase III Nasopharyngeal Carcinoma Research Results Successfully Held, Streamed on ESMO Official Website | SHANGHAI, Oct. 24, 2025 /PRNewswire/ -- At 15:00 Beijing Time (09:00 am Berlin Time) on October 20, the "Global Launch Event for Iza-bren (EGFR×HER3 Bispecific ADC) Nasopharyngeal Carcinoma BL-B01D1-303 Research Results" was held ... |
| 21.10.2025 | Faeth Therapeutics Secures $25M to Propel Cancer Metabolism Therapies | Faeth Therapeutics secured $25 million, raising its total capital to $92 million. This vital funding drives its lead PIKTOR program for endometrial cancer into Phase 2, following an impressive 80% response rate. It also expands the AI-drive... |
| 20.10.2025 | Antengene Presents Latest ATG-022 Clinical Data at ESMO 2025 Demonstrating Efficacy Across All CLDN18.2 Expression Levels and Exceptional Tolerability | SHANGHAI and HONG KONG, Oct. 20, 2025 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializi... |
| 20.10.2025 | HanchorBio Showcases Pipeline Momentum with HCB101 and HCB301 Data Across Five Major Oncology Meetings in Q4 2025 | Presentations highlight HCB101's differentiated profile and introduce first preclinical data from HCB301, underscoring HanchorBio's innovation in next-generation immunotherapies
TAIPEI, SHANGHAI and SAN FRANCISCO, Oct. 20, 2025 /PRNewswire/... |
| 20.10.2025 | Alphamab Oncology Presented Multiple Clinical Data on Biparatopic HER2-targeting ADC JSKN003 at ESMO Congress 2025 | SUZHOU, China, Oct. 20, 2025 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that two latest clinical data on biparatopic HER2-targeting antibody-drug conjugate (ADC) JSKN003 for the treatment of primary platinum-refractor... |
| 20.10.2025 | Live from ESMO | Hengrui Debuts Exhibition Booth with Landmark Data Showcasing Pharma's Emerging Innovation Power | BERLIN, Oct. 20, 2025 /PRNewswire/ -- From October 17 to 21, the European Society for Medical Oncology (ESMO) Annual Congress convened in Berlin, bringing together global leaders in oncology and pharmaceutical innovation. Representing China... |
| 20.10.2025 | Positive Results from Phase 3 OptiTROP-Lung04 Trial of Sacituzumab Tirumotecan Presented at ESMO Presidential Symposium and Simultaneously Published in NEJM | CHENGDU, China, Oct. 20, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that at the 2025 European Society for Medical Oncology (ESMO) Congress held in Berlin, Germany, results from... |
| 20.10.2025 | Faeth Therapeutics: $25 Million Raised To Advance PIKTOR Phase 2 Trial Following 80% Response Rate In Endometrial Cancer | Faeth Therapeutics, a clinical-stage biotechnology company pioneering metabolism-based cancer therapies, announced a $25 million strategic financing round to advance its lead program, PIKTOR, in endometrial cancer. The raise brings Faeth’s ... |
| 20.10.2025 | ESMO 2025: CStone Discloses Phase I Data for CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody) | SUZHOU, China, Oct. 20, 2025 /PRNewswire/ -- CStone Pharmaceuticals ("CStone," HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of therapies for oncology, autoimmune/inflammation,... |
| 20.10.2025 | ESMO Congress 2025 Presidential Symposium Oral Presentation | Disitamab Vedotin Achieves Major Breakthrough as First-Line Treatment for Urothelial Carcinoma | BERLIN, Oct. 20, 2025 /PRNewswire/ -- At the 2025 European Society for Medical Oncology (ESMO) Congress, a Phase III clinical study on disitamab vedotin plus toripalimab versus chemotherapy as first-line treatment for HER2-expressing locall... |
| 19.10.2025 | Multitude Therapeutics Announces Encouraging Interim Phase I/II Results from Ongoing First-in-Human Study Evaluating its MUC18-directed Antibody-Drug-Conjugate, AMT-253, in Melanoma and Other Advanced... | AMT-253 is a potential first-in-class MUC18-directed ADC with a proprietary linker-payload design
AMT-253 demonstrated a manageable safety profile, consistent with other TOP1-inhibitor based ADCs
Promising antitumor activity was observed in... |
| 19.10.2025 | Significant OS Benefit with Cadonilimab in First-Line Advanced Gastric Cancer: Final Analysis of COMPASSION-15 Presented at ESMO 2025 | HONG KONG, Oct. 19, 2025 /PRNewswire/ -- On October 19, 2025, Akeso (9926.HK) announced the final analysis results from the COMPASSION-15/AK104-302 study at the 2025 European Society of Medical Oncology Congress (ESMO 2025) . COMPASSION-15 ... |
| 18.10.2025 | SCG announces presentation of clinical results of SCG142 in patients with HPV-related carcinoma at ESMO 2025 | SINGAPORE, Oct. 18, 2025 /PRNewswire/ -- SCG Cell Therapy Pte Ltd (SCG), a clinical-stage biotechnology company developing next-generation immunotherapies for infectious diseases and their associated cancers, announced the presentation of f... |
| 17.10.2025 | Kelun-Biotech's Core product Trastuzumab Botidotin Approved for Marketing by NMPA for HER2-positive BC | CHENGDU, China, Oct. 17, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that the Company's human epidermal growth factor receptor 2 (HER2)-directed antibody-drug conjugate (ADC) tr... |
| 17.10.2025 | Multitude Therapeutics Announces Promising Interim Phase I/II Results from the Ongoing First-in-Human Study Evaluating its CD44v9-directed Antibody-Drug-Conjugate, AMT-116, in Heavily Pretreated EGFR ... | AMT-116 is a potential first-in-class CD44v9-directed Topoisomerase I inhibitor-based ADC
AMT-116 demonstrated a favorable safety profile, with manageable hematologic and Gastrointestinal toxicities
Promising efficacies were observed in pat... |
| 15.10.2025 | Mabwell Announces Latest Clinical Results of Novel B7-H3-Targeting ADC 7MW3711 to Be Presented at 2025 ESMO Congress | SHANGHAI, Oct. 15, 2025 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that clinical research results of its novel B7-H3-targeting ADC (R&D code: 7MW3711) for multiple ... |
| 14.10.2025 | Great Novel Therapeutics Biotech & Medicals Corporation (GNTbm) Presented Preclinical Data on GNTbm-TKI, a Novel Multi-tyrosine Kinase Inhibitor with Potent Immune Activation, at the 2025 ESMO Ann... | TAIPEI, Oct. 14, 2025 /PRNewswire/ -- GNTbm (stock code: 7427, Taiwan) announced the preclinical data on GNTbm-TKI, a novel multi-receptor tyrosine kinase inhibitor for cancer immunotherapy. GNTbm-TKI will be presented as posters at the 202... |
| 14.10.2025 | Lunit AI Predicts Immunotherapy Outcome in Colorectal, Kidney, and Lung Cancer at ESMO 2025 | AI-powered histopathology demonstrates predictive value for immunotherapy outcomes in pMMR mCRC, advanced ccRCC, and NSCLC with data featured in both oral and poster presentations
SEOUL, South Korea, Oct. 14, 2025 /PRNewswire/ -- Lunit (KRX... |
| 13.10.2025 | Clinical milestones bring startups closer to launching new therapies |
Following a positive meeting with the U.S. Food and Drug Administration (FDA), Oculis is advancing Privosegtor, a new peptoid small molecule candidate with the potential to become the first neuroprotective therapy for acute optic neuritis ... |
| 30.09.2025 | CHOSA announces positive results from a clinical study in collaboration with ETOP/EORTC on platinum predictor in lung cancer | CHOSA announces positive results from a clinical study in collaboration with ETOP/EORTC on platinum predictor in lung cancer
Tue, Sep 30, 2025 13:03 CET Report this content
The English text is an unofficial translation. In case of any discr... |
| 08.08.2025 | CHOSA’s presents data on the carboplatin response predictor in breast cancer patients on the annual ESMO conference | CHOSA’s presents data on the carboplatin response predictor in breast cancer patients on the annual ESMO conference
Fri, Aug 08, 2025 08:00 CET Report this content
The English text is an unofficial translation. In case of any discrepancies ... |
| 30.07.2025 | Harbour BioMed to Present Phase II Data of HBM4003 and Tislelizumab Combination in MSS Metastatic Colorectal Cancer at ESMO 2025 | CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, July 30, 2025 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company focused on the discovery and development of novel antibody therapeutics in immunology and ... |
| 04.07.2025 | Imfinzi approved in the EU for bladder cancer | Imfinzi approved in the EU for bladder cancer
Fri, Jul 04, 2025 08:00 CET Report this content
4 July 2025
Imfinzi approved in the EU as first and only perioperative
immunotherapy for muscle-invasive bladder cancer
Approval based on NIAGARA ... |
| 03.07.2025 | Dizal's ZEGFROVY® (sunvozertinib) Receives FDA Accelerated Approval as the Only Targeted Oral Treatment for Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations | ZEGFROVY is the only approved targeted oral treatment for NSCLC with EGFR exon20ins
Approval follows the U.S. FDA's Priority Review and is supported by the pivotal WU-KONG1 Part B study, in which ZEGFROVY demonstrated statistically signific... |
| 02.07.2025 | CMI Media Group Announces 2025 Agility Berlin; Martin Strobel to Keynote | Strategic media healthcare agency CMI Media Group, a WPP company, is proud to announce the inaugural European event, Agility Berlin: Transformative Thinking, Rx Precision in Healthcare Marketing, featuring Martin Strobel as keynote. Strobel... |
| 29.04.2025 | Telix's Illuccix PSMA-PET Imaging Agent Approved in France | New approval provides French hospitals and clinics with access to a proven PSMA-PET imaging agent
MELBOURNE, Australia, April 29, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the Company) today announces... |
| 21.03.2025 | Antengene Announces 2024 Full-Year Financial Results, Proprietary Programs Advancing to Pivotal Trials with Accelerating Multi-market Revenue Ramp Up | SHANGHAI and HONG KONG, March 21, 2025 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) today announced its full-year results for the period ending December 31, 2024, along with several significant milest... |
| 13.02.2025 | Illuccix® Approved in the United Kingdom | MELBOURNE, Australia, Feb. 13, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that the United Kingdom (UK) Medicines and Healthcare Products Regulatory Agency (MHRA) has approv... |
| 10.02.2025 | CStone Announces Inclusion of Cejemly® (sugemalimab) as a First-Line Combination Therapy for NSCLC in ESMO Guideline | SUZHOU, China, Feb. 10, 2025 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of anti-cancer therapies, today announced that its ... |
| 13.12.2024 | Alphamab Oncology Presented the Phase II Clinical Data of KN046 in Combination with Axitinib for the Treatment of Advanced NSCLC at ESMO IO Congress 2024 | SUZHOU, China, Dec. 13, 2024 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that the latest clinical data from a phase II clinical study on PD-L1/CTLA-4 bispecific antibody KN046 in combination with axitinib as first-line... |
| 10.12.2024 | Longer-term Novartis Kisqali® NATALEE data show durable reduction in distant recurrence in broad population of patients with early breast cancer | Reduction in distant recurrence consistently deepened beyond 3-year Kisqali treatment duration in patients with node-positive (N+) and high-risk node-negative (N0) disease, as well as between anatomical stages1
Real-world 5-year distant rec... |
| 22.11.2024 | Akeso's Penpulimab Combination Therapy for First-line Treatment of Hepatocellular Carcinoma Accepted by NMPA | HONG KONG, Nov. 22, 2024 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that the National Medical Products Administration (NMPA) of China has accepted its supplemental new drug application (sN... |
| 22.11.2024 | Metropolis Healthcare unveils Key Findings from Molecular Genomics Study in honour of Lung Cancer Awareness Month | Mumbai, Maharashtra, India
Lung cancer remains one of the most prevalent and deadly cancers globally, with approximately 2.2 million new cases diagnosed annually, contributing to 18% of all cancer-related deaths, according to the Internatio... |
| 18.10.2024 | Novartis receives positive CHMP opinion for Kisqali® to help reduce risk of recurrence in people with HR+/HER2- early breast cancer | If approved, patients in Europe with stage II or III HR+/HER2- early breast cancer (EBC) at high risk of recurrence, including those with node-negative disease, will be eligible for adjuvant treatment with Kisqali® (ribociclib) in combinati... |
| 17.09.2024 | FDA approves Novartis Kisqali® to reduce risk of recurrence in people with HR+/HER2- early breast cancer | Ad hoc announcement pursuant to Art. 53 LR
Broad indication in HR+/HER2- stage II and III early breast cancer (EBC) at high risk of recurrence approximately doubles population eligible for CDK4/6 inhibitor adjuvant therapy1,2
Kisqali® (ribo... |
| 14.09.2024 | MediLink presents YL201 (B7H3 ADC) at ESMO 2024, with over 6-months PFS in SCLC, and showing pan-tumor benefits | The first publication of clinical data for YL201, featured in an oral presentation at ESMO 2024.
Encouraging antitumor activity of YL201 in multiple solid tumor types, including SCLC, NPC, and wild-type NSCLC, from Phase I escalation and ex... |
| 12.07.2024 | Senhwa Biosciences Clinical Data Abstract of Pidnarulex Accepted for Presentation at 2024 ESMO Congress | TAIPEI and SAN DIEGO, July 12, 2024 /PRNewswire/ -- Senhwa Biosciences' new drug Pidnarulex (CX-5461) has demonstrated efficacy in treating various solid tumors with BRCA2 or PALB2 gene defects. The abstract of this clinical trial has been ... |
| 27.06.2024 | BioStock: Medivir presents promising results in difficult-to-treat patient population | BioStock: Medivir presents promising results in difficult-to-treat patient population
Thu, Jun 27, 2024 10:00 CET Report this content
Medivir today presents new clinical data from its phase Ib/IIa study at ESMO GI in Munich. The company's c... |
| 14.06.2024 | Innovent Delivers Oral Presentation on Clinical Data of IBI363 (First-in-class PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) in Advanced Non-small Cell Lung Cancer and Other Solid Tumors at the ... | SAN FRANCISCO and SUZHOU, China, June 14, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for ... |
| 05.06.2024 | I-Mab Announces Collaboration with Bristol Myers Squibb to Evaluate Givastomig in a Combination Study for Newly Diagnosed Gastric and Esophageal Cancers | I-Mab enters clinical collaboration with Bristol Myers Squibb to evaluate Claudin 18.2 x 4-1BB bispecific antibody givastomig in combination with nivolumab and chemotherapy for the treatment of gastric and esophageal cancer.
Collaboration b... |
| 02.06.2024 | Innovent Presents Phase 1 Clinical Data of First-in-class PD-1/IL-2α Bispecific Antibody Fusion Protein (IBI363) in Melanoma, Colorectal Cancer and other Solid Tumors at the 2024 ASCO Annual Meeting | SAN FRANCISCO, U.S. and SUZHOU, China, June 2, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines... |
| 02.06.2024 | Innovent Presents at the 2024 ASCO Annual Meeting on Clinical Data of anti-CLDN18.2 ADC (IBI343) in Patients with Advanced Pancreatic Cancer or Biliary Tract Cancer | SAN FRANCISCO, U.S. and SUZHOU, China, June 2, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines... |
| 29.04.2024 | Medivir to present data for the combination of fostrox + Lenvima in HCC at ESMO GI | Medivir to present data for the combination of fostrox + Lenvima in HCC at ESMO GI
Mon, Apr 29, 2024 10:00 CET Report this content
Stockholm — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative tr... |
| 19.04.2024 | GenFleet Therapeutics Announces FDA's Clinical Trial Approval for GFH925 (KRAS G12C Inhibitor) Monotherapy in Phase III Registrational Study Treating Metastatic Colorectal Cancer | SHANGHAI, April 19, 2024 /PRNewswire/ -- GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, announced US Food and Drug Administration (FDA) has granted the clinical t... |
| 08.04.2024 | OncoZenge Announces Dr. Paolo Bossi as New Member of the Advisory Board | OncoZenge Announces Dr. Paolo Bossi as New Member of the Advisory Board
Mon, Apr 08, 2024 09:30 CET Report this content
Stockholm, Sweden – April 8 2024 – OncoZenge AB (publ), a leading pharmaceutical company developing BupiZenge™, an innov... |
| 29.03.2024 | Jacobio Pharma Announces 2023 Annual Results | BEIJING, SHANGHAI and BOSTON, March 29, 2024 Jacobio/PRNewswire/ -- Pharma (1167.HK), a clinical-stage oncology company drugging the undruggable targets, today announced its 2023 annual results. The revenue was RMB63.5 million, the R&D ... |
| 21.03.2024 | Henlius 2023 Annual Results: Revenue surpassed RMB5.39 billion with a net profit RMB546 million, first full-year profitability achieved | SHANGHAI, March 21, 2024 /PRNewswire/ -- Henlius (2696.HK) announced its 2023 annual results. During the reporting period, Henlius' revenue reached about RMB5.3949 billion, representing an increase of 67.8% YoY, and recorded a net profit of... |
| 07.03.2024 | Luye Pharma's Innovative Drug Zepzelca® (Lurbinectedin) Launched in Hong Kong and Macao | Reshaping the landscape for the second-line treatments of Small Cell Lung Cancer
HONG KONG and MACAO, March 7, 2024 /PRNewswire/ -- A symposium called the New Treatment Paradigm for Small Cell Lung Cancer (SCLC) organized by the Hong Kong C... |
| 08.12.2023 | Latest Novartis Kisqali® NATALEE analysis reinforces 25% reduction in risk of recurrence across broad population of patients with early breast cancer; supports regulatory submissions | With 5.6 months of additional follow-up and 78.3% of patients having completed Kisqali® (ribociclib) investigational treatment, the updated analysis shows sustained iDFS benefit and stability in secondary endpoints including overall surviva... |
| 06.12.2023 | TiumBio, a Biotech Company Gets Selected as One of Outstanding Startups at the Super Gap Startup 1000+ Tech Conference | TiumBio Logo
Thiumbio CEO Kim Huntaek receives the 10 outstanding startup companies (Image courtesy of TiumBio)
Poster presented at the European Society of Medical Oncology (Image courtesy of TiumBio) PANGYO, SUNGNAM, SOUTH KOREA, December ... |
| 22.10.2023 | Jacobio Pharma Presents Clinical Results of Glecirasib in Combination with JAB-3312 at ESMO | The ORR (objective response rate) and the DCR (disease control rate) in the frontline setting of glecirasib (KRAS G12C Inhibitor) in combination with JAB-3312 (SHP2 inhibitor) were 65.5% (38/58) and 100% respectively in all dose groups of a... |
| 31.08.2023 | Lytix Biopharma presents first half and second quarter 2023 results | Lytix Biopharma presents first half and second quarter 2023 results
Thu, Aug 31, 2023 08:00 CET Report this content
Building a Phase II evidence base
Oslo, 31 August 2023. Lytix Biopharma – Lytix Biopharma AS (“Lytix”) (Euronext Growth Oslo... |
| 21.07.2023 | Jacobio Pharma to Present Data of Glecirasib in Combination with JAB-3312 at the 2023 ESMO Conference | BEIJING and SHANGHAI and BOSTON, July 21, 2023 /PRNewswire/ -- Jacobio Pharma (1167.HK), a clinical-stage oncology company focusing on undruggable targets, is pleased to announce today that the company will present its clinical results in t... |
| 20.07.2023 | Lytix Biopharma announces presentation of interim data from ATLAS-IT-05 study at ESMO 2023. | Lytix Biopharma announces presentation of interim data from ATLAS-IT-05 study at ESMO 2023.
Thu, Jul 20, 2023 09:00 CET Report this content
Oslo, 20 July 2023. Lytix Biopharma – Lytix Biopharma AS (“Lytix”) (Euronext Growth Oslo: LYTIX), a ... |
| 08.01.2023 | Глубокое обучение в диагностике: как AI спасает жизни и экономит средства на лечение | Разница между современными моделями ML и XAI. Источник: DARPA
Разрабатываемые сейчас решения XAI просты и находят ограниченное применение. Однако ожидается, что такие алгоритмы со временем станут доминировать в здравоохранении, поскольку он... |
| 28.12.2022 | Imfinzi, Imjudo approved in Japan for 3 cancers | Imfinzi, Imjudo approved in Japan for 3 cancers
Wed, Dec 28, 2022 08:00 CET Report this content
28 December 2022 07:00 GMT
Imfinzi plus Imjudo approved in Japan for advanced liver and non-small cell lung cancers, and Imfinzi approved for un... |
| 06.12.2022 | Глубокое обучение в диагностике: как AI спасает жизни и экономит средства на лечение | «Симптомы никогда не лгут», — так сказал самый блестящий диагност, доктор Хаус, который, увы существует только в телесериале. В реальной жизни симптомы часто нелегко обнаружить даже лучшим специалистам, а ошибочные диагнозы признаны самыми ... |
| 02.12.2022 | Jacobio's Preclinical Results of KRAS G12C Inhibitor in Combination with SHP2 Inhibitor Will be Presented at the ESMO Asia Congress 2022 | BEIJING, SHANGHAI and BOSTON, Dec. 2, 2022 /PRNewswire/ -- Jacobio Pharma (1167.HK) will present the results of KRAS G12C inhibitor JAB-21822 as a single agent or in combination with SHP2 inhibitor JAB-3312 in preclinical cancer models in a... |
| 10.09.2022 | ESMO 2022 - Great oaks grow from small acorns: oncology is committed to doing its part for sustainability | PARIS, Sept. 10, 2022 /PRNewswire/ -- At ESMO 2022, 9-13 September, Paris, France, the premier cancer congress in Europe, which has gathered 28k participants from 167 countries, many discussions will be around sustainability, prevention and... |
| 09.09.2022 | Novartis Kisqali® adds one more year of survival benefit for broadest set of patients, including those with aggressive HR+/HER2- advanced breast cancer | New large pooled exploratory analysis from MONALEESA-2, -3 and -7 reinforces unparalleled overall survival (OS) benefit of Kisqali plus ET compared to ET alone, in HR+/HER2- aBC patients with challenging visceral metastases1
Kisqali plus en... |
| 06.09.2022 | Iovance Biotherapeutics to Present Posters at ESMO 2022 | SAN CARLOS, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced the publication of abstracts repor... |
| 18.07.2022 | I-Mab to Present Phase 2 Clinical Data of CD47 Antibody Lemzoparlimab at ESMO Congress 2022 | GAITHERSBURG, Md. and SHANGHAI, July 18, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, toda... |
| 04.05.2022 | New Novartis data demonstrate only Kisqali® offers more life in the first-line setting for postmenopausal HR+/HER2- advanced breast cancer patients | With further follow-up of MONALEESA-3, Kisqali plus fulvestrant achieved a median overall survival (OS) of more than five-and-a-half years (67.6 months) in the first-line (1L) setting for postmenopausal women living with HR+/HER2- aBC1
When... |
| 07.04.2022 | ExpreS2ion will participate in key industry and investor events | ExpreS2ion will participate in key industry and investor events
Thu, Apr 07, 2022 13:00 CET Report this content
Hørsholm, Denmark, April 7, 2022 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") ... |
| 19.01.2022 | Imfinzi plus chemotherapy reduced risk of death by 20% in 1st-line advanced biliary tract cancer | * TOPAZ-1 is the first Phase III trial to show improved survival with an immunotherapy combination in this setting
Combination did not increase discontinuations due to adverse events vs. chemotherapy alone
Positive results from the TOPAZ-1 ... |
| 19.01.2022 | AstraZeneca : Imfinzi plus chemotherapy reduced risk of death by 20% in 1st-line advanced biliary tract cancer | PUBLISHED18 January 2022
18 January 2022 22:05 GMT
TOPAZ-1 is the first Phase III trial to show improved survival with an immunotherapy combination in this setting
Combination did not increase discontinuations due to adverse events vs. chem... |
| 25.10.2021 | Imfinzi improved survival in biliary tract cancer | Imfinzi improved survival in biliary tract cancer Mon, Oct 25, 2021 08:00 CET
25 October 2021 7:00 BST
Imfinzi plus chemotherapy significantly improved overall survival in 1st-line advanced biliary tract cancer in TOPAZ-1 Phase III trial at... |
| 20.09.2021 | Veru : Announces Positive Updated Data from Phase 1b/2 Sabizabulin Study in Men with Metastatic Castration Resistant Prostate Cancer at the 2021 ESMO Congress | MIAMI, Sept. 20, 2021 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate and breast cancer, today announced that updated clinical dat... |
| 15.09.2021 | Epizyme : Announces Data from TAZVERIK (Tazemetostat) Clinical Programs to be Presented During Poster Sessions at 2021 ESMO Virtual Congress | CAMBRIDGE, Mass. - Epizyme, Inc. (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, announced that clinical data will be presented at the upcoming 2021 Europe... |
| 13.09.2021 | Cantargia: New positive interim results on nadunolimab combination therapy in NSCLC published in abstract for the annual ESMO Congress | Cantargia: New positive interim results on nadunolimab combination therapy in NSCLC published in abstract for the annual ESMO Congress Mon, Sep 13, 2021 00:05 CET
Cantargia AB today announced the publication of an abstract disclosing novel ... |
| 09.09.2021 | Veru : Announces Oral Presentation of Updated Data from the Phase 1b/2 Sabizabulin Study in Men with Metastatic Castration Resistant Prostate Cancer at the 2021 ESMO Congress | MIAMI, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate and breast cancer, today announced that updated clinical dat... |
| 30.08.2021 | Targovax ASA : - Abstract on ONCOS-102 phase 1 trial in advanced PD1 refractory melanoma is accepted at ESMO Congress | Oslo, Norway - Targovax ASA (OSE: TRVX), a clinical stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors, announces that the abstract 'A pilot study of Engineered Adenovirus ONCOS-102 in combinatio... |
